Repatha® (evolocumab) can be used to help adults at increased risk for major adverse cardiovascular events lower their LDL-C ...

These drugs promise faster results with fewer side effects, and in some cases, reversal or slows the disease progression.

Amgen has reported positive results from its phase 3 VESALIUS-CV trial, which demonstrated that Repatha (evolocumab) ...

AUSTIN, Texas and TOKYO, Nov. 14, 2025 /PRNewswire/ -- According to DataM Intelligence, the Cardiovascular Biologics Market Size was valued at approximately USD 2.20 billion in 2024 and is projected ...

New drugs that lower cholesterol and treat hyperlipidemia are preparing to enter the market. According to The New York Times (NYT) and The Wall Street Journal (WSJ) on the 9th, U.S. pharmaceutical ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

The Trump administration has notified the U.S. Supreme Court that it still wants to fight a lower court ruling requiring full SNAP benefits be paid for November. The move comes after an appeals court ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, ...

Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...